Vaccitech Stock Forecast, Price & News

-0.07 (-0.46 %)
(As of 08/4/2021 11:34 AM ET)
Today's Range
50-Day Range
52-Week Range
Volume11 shs
Average Volume18,744 shs
Market Capitalization$514.95 million
P/E RatioN/A
Dividend YieldN/A
30 days | 90 days | 365 days | Advanced Chart
Receive VACC News and Ratings via Email

Sign-up to receive the latest news and ratings for Vaccitech and its competitors with MarketBeat's FREE daily newsletter.

About Vaccitech

Vaccitech plc, a clinical-stage biopharmaceutical company, engages in the discovery and development of novel T cell immunotherapeutics and vaccines for the treatment and prevention of infectious diseases and cancers. Its therapeutic programs include VTP-300, indicated for the treatment of chronic hepatitis B infection; VTP-200, indicated for the treatment of human papilloma virus infection; VTP-850, indicated for the treatment of prostate cancer; and VTP-600, indicated for the treatment of non-small cell lung cancer. The company's prophylactic programs include VTP-400 for the prevention of herpes zoster or shingles; and VTP-500 for the prevention of Middle East respiratory syndrome. In addition, it is developing a COVID-19 vaccine with the University of Oxford, which is approved for use in various territories and licensed worldwide to AstraZeneca through Oxford University Innovation. Vaccitech plc was formerly known as Vaccitech Rx Limited and changed its name to Vaccitech plc on March 31, 2021. Vaccitech plc was founded in 2016 and is headquartered in Oxford, United Kingdom.


See More Headlines

Industry, Sector and Symbol

Sales & Book Value






Overall MarketRank

2.16 out of 5 stars

Medical Sector

394th out of 1,309 stocks

Pharmaceutical Preparations Industry

199th out of 646 stocks

Analyst Opinion: 3.5Community Rank: 5.0Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 0.6 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles

Vaccitech (NASDAQ:VACC) Frequently Asked Questions

Is Vaccitech a buy right now?

4 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Vaccitech in the last twelve months. There are currently 4 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" Vaccitech stock.
View analyst ratings for Vaccitech
or view top-rated stocks.

What stocks does MarketBeat like better than Vaccitech?

Wall Street analysts have given Vaccitech a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Vaccitech wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

How were Vaccitech's earnings last quarter?

Vaccitech plc (NASDAQ:VACC) released its quarterly earnings data on Monday, June, 14th. The company reported ($0.96) earnings per share for the quarter, topping the Thomson Reuters' consensus estimate of ($1.21) by $0.25. The firm earned $0.22 million during the quarter, compared to analyst estimates of $0.10 million.
View Vaccitech's earnings history

What price target have analysts set for VACC?

4 brokers have issued twelve-month price targets for Vaccitech's shares. Their forecasts range from $22.00 to $28.00. On average, they expect Vaccitech's stock price to reach $25.00 in the next year. This suggests a possible upside of 65.9% from the stock's current price.
View analysts' price targets for Vaccitech
or view top-rated stocks among Wall Street analysts.

Who are Vaccitech's key executives?

Vaccitech's management team includes the following people:
  • Mr. William J. Enright, CEO & Board Director (Age 58, Pay $572.88k)
  • Prof. Sarah Gilbert, Co-Founder
  • Prof. Adrian Hill, Co-Founder & Scientific Advisor
  • Mr. Georgy Egorov, Chief Financial Officer
  • Dr. Margaret Marshall M.D., Chief Medical Officer
  • Mr. Chris Ellis, Chief Operating Officer
  • Dr. Thomas George Evans, Chief Scientific Officer
  • Mr. Graham Griffiths, Chief Bus. Officer
  • Ms. Elizabeth Eagling-Vose, Head of Clinical Operations
  • Bernie McDonald, Head of IP

Who are some of Vaccitech's key competitors?

When did Vaccitech IPO?

(VACC) raised $110 million in an initial public offering on Friday, April 30th 2021. The company issued 6,500,000 shares at $16.00-$18.00 per share. Morgan Stanley, Jefferies, Barclays and William Blair served as the underwriters for the IPO and H.C. Wainwright & Co., LLC was co-manager.

What is Vaccitech's stock symbol?

Vaccitech trades on the NASDAQ under the ticker symbol "VACC."

When does the company's lock-up period expire?

Vaccitech's lock-up period expires on Wednesday, October 27th. Vaccitech had issued 6,500,000 shares in its IPO on April 30th. The total size of the offering was $110,500,000 based on an initial share price of $17.00. After the expiration of the company's lock-up period, major shareholders and company insiders will be able to sell their shares of the company.

How do I buy shares of Vaccitech?

Shares of VACC can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Vaccitech's stock price today?

One share of VACC stock can currently be purchased for approximately $15.07.

How much money does Vaccitech make?

Vaccitech has a market capitalization of $517.35 million and generates $4.82 million in revenue each year.

How many employees does Vaccitech have?

Vaccitech employs 49 workers across the globe.

What is Vaccitech's official website?

The official website for Vaccitech is

Where are Vaccitech's headquarters?


How can I contact Vaccitech?

Vaccitech's mailing address is THE SCHRODINGER BUILDING HEATLEY ROAD THE OXFORD SCIENCE PARK, OXFORD X0, OX4 4GE. The company can be reached via phone at 44 1865 818 808 or via email at [email protected]

This page was last updated on 8/4/2021 by Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.